Cross Country Healthcare Inc
What Analysts Recommend for Amedisys and Peers in March 2018
Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating.
Analyst Ratings for BioTelemetry and Its Peers in March 2018
Of the seven analysts covering BioTelemetry in March 2018, two have given it a “strong buy” rating, and five have given it a “buy.”
Understanding BioTelemetry’s Business Strategy
BioTelemetry’s (BEAT) business strategy is to solidify its position as a leading provider of outpatient cardiac monitoring services.